Business Wire

nShift: Retailers urged to integrate customer data as 84% of execs struggle with data silos

4.9.2024 16:49:00 CEST | Business Wire | Press release

Share

New nShift guide draws attention to untapped data within delivery and post-purchase processes

Disparate data could be causing retailers to miss crucial commercial opportunities as 84% of execs confess that they have felt the effects of “data silos”.1 This is causing them to miss out on crucial data from the delivery process which often sits across different systems and multiple businesses.

In a new report, nShift, the global leader in experience and delivery management (DMXM) is encouraging retailers to make the most of data generated during the delivery and post-purchase experience.

Retailers have increasingly used large data collections to help improve their sales and operations. A new report by nShift, “Creating a data-driven delivery experience” argues that too often, retailers are missing crucial insights from the delivery and post-purchase process. Typically, such data sits in silos across the organization – or with external carrier companies - making it difficult to use effectively.

Sean Sherwin-Smith, post-purchase product director at nShift said: “The delivery process is a fantastic example of where retailers sit upon a wealth of untapped data. Information from the delivery and post-purchase process can shine a real light on how retailers and warehouses can improve efficiency, revamp the customer experience and turn one-off purchases into lifelong customer relationships.

“The problem is that retailers tend to view the fulfillment process and the customer experience as two separate things. As a result, data sits in disjointed systems and is rarely compiled and analyzed. Only by bringing deliveries and experience management together can retailers tap into crucial insights and create data-driven growth strategies.”

The new nShift report explores how leveraging data from the delivery and post-purchase experience can help retailers:

  1. Optimize and reduce carrier costs - the greater access a retailer or warehouse has to carrier costs and performance data, the more easily they can select the most cost-effective last-mile delivery option for each shipment
  2. Improve conversions at checkout – by ensuring that a shopper sees the delivery option they want at the top of the list of choices
  3. Create better customer communications – retailers can then create relevant communications to match how often, according to data, people are checking updates and weave in product plugs or brand messages as appropriate
  4. Increase customer loyalty by keeping their delivery promise – comparing performance data across carrier companies enables retailers to drive up standards and negotiate better results
  5. Retain more revenue by reducing volumes – by paying close attention to what issues are causing people to send products back and addressing such issues with product and marketing teams
  6. Influence consumer behavior – to encourage more shoppers into physical stores or to alter their returns habits

nShift’s DMXM suits of solutions bring together core components of delivery management (such as label printing and carrier booking) with cutting-edge consumer applications. Because delivery management, order tracking, checkout and returns all sit on one platform, it’s easy to join up the relevant data. A range of easy-to-use dashboards makes insights clear, digestible, sharable and actionable.

Read the full report: “Creating a data-driven delivery experience: how delivery and experience management (DMXM) unlocks business-changing insights for online retailers

About nShift

nShift’s delivery & experience management (DMXM) platform drives ecommerce success. Grow beyond limits with constant innovation and the world’s largest carrier network. Build customer loyalty with end-to-end tools that enhance experience. Unify data into usable insight that connects and optimizes processes. With nShift, make delivery the essential link between your brand and your customers.

nShift. Worry less. Ship smarter. www.nshift.com

1https://www.mckinsey.com/capabilities/growth-marketing-and-sales/our-insights/the-value-of-getting-personalization-right-or-wrong-is-multiplying

View source version on businesswire.com: https://www.businesswire.com/news/home/20240904597279/en/

Contacts

James Ellerington: James.Ellerington@fourteenforty.uk / (+44) 07725 534941

James Ellerington: James.Ellerington@fourteenforty.uk / (+44) 07725 534941

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye